Oncology

Persistent PSA After Radical Prostatectomy: A Marker of Mortality Risk?

A large cohort study published in JAMA Oncology examines the implications of persistent prostate-specific antigen (PSA) levels after radical prostatectomy (RP), raising important questions about monitoring duration and treatment timing in prostate cancer. 🎯 Objective To determine if persistent PSA levels post-RP predict increased mortality risk, an

Comparative RNA Expression in Pediatric Cancers: A New Tool for Precision Medicine

This study from the UC Santa Cruz Treehouse Childhood Cancer Initiative and Stanford University School of Medicine demonstrates the clinical potential of Comparative Analysis of RNA Expression (CARE) in pediatric and young adult cancers—especially when DNA mutations alone aren't enough to guide treatment. 🎯 Objective To evaluate whether RNA-Seq analysis can identify

Adjuvant Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer: No Survival Advantage

A major cohort study published in JAMA Oncology challenges the common practice of combining chemotherapy with radiotherapy after surgery in patients with intermediate-risk cervical cancer, finding no survival benefit over radiotherapy alone. 🎯 Study Objective To evaluate whether adjuvant chemoradiotherapy (CRT) offers superior overall survival compared to r

RAMOSE Study Results: Ramucirumab Combined With Osimertinib Shows Benefits in Patients With EGFR-Mutant Metastatic Lung Cancer

EGFR-mutated non-small cell lung cancer (NSCLC) represents one of the most aggressive forms of lung cancer. The RAMOSE study, a phase II clinical trial, investigated the combination of ramucirumab with osimertinib for patients with metastatic lung cancer not previously treated with EGFR-targeted tyrosine kinase inhibitors (TKI). The aim was to evaluate the efficacy and safety of this combination compared to osimertinib monotherapy.The study methodology involved 159 patients randomly as

Radical prostatectomy (RP) vs. radiation therapy (RT) in high-risk prostate cancer (HR-PCa): Randomized comparison emulated with individual patient data (IPD) from two phase III randomized controlled trials (RCTs).

In general, standard of care (SOC) treatment options for high-risk prostate cancer (HR- PCa) include: radiotherapy (RT) with long-term androgen deprivation (LT-ADT) or radical prostatectomy (RP) with selective use of postoperative RT +/- androgen deprivation therapy (ADT). Retrospective population-based and multicenter studies have evaluated the optimal approach but have produced divergent results. Thus, the present study performed an emulated randomized comparison of RT vs. RP in high-risk p

PRESIDENTIAL Study: Evaluation of Enzalutamide in Combination With Chemotherapy in Patients With Metastatic Prostate Cancer

The PRESIDE study was conducted to evaluate the continued efficacy of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed after initial docetaxel therapy. The aim was to determine whether maintaining enzalutamide in combination with subsequent chemotherapy could offer additional benefits compared to chemotherapy alone.The study design was multicenter, randomized, and double-blind. Patients were initially treated with enzalutamide monothe

Usefulness of the two-dimensional echocardiogram in the diagnosis of severe coronary stenosis in patients with acute coronary syndrome without ST-segment elevation

Introduction:Echocardiogram in patients with non-ST-segment elevation acute coronary syndrome (NSTEACS) can detect the location and extent of wall motion abnormalities and thus infer the severity of coronary lesions.Objective:

Cardiology